Dermata Therapeutics Files 8-K: Material Agreement & Equity Sales

TL;DR

Dermata Therapeutics (DRMA) filed an 8-K on 12/23/25 detailing a material agreement and equity sales.

AI Summary

Dermata Therapeutics, Inc. announced on December 23, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events. The filing includes financial statements and exhibits.

Why It Matters

This 8-K filing indicates significant corporate activity for Dermata Therapeutics, including a new material agreement and equity transactions, which could impact its financial standing and future operations.

Risk Assessment

Risk Level: medium — Material definitive agreements and unregistered equity sales can introduce financial and operational risks, requiring careful investor scrutiny.

Key Players & Entities

• Dermata Therapeutics, Inc. (company) — Registrant
• December 23, 2025 (date) — Date of earliest event reported
• 001-40739 (other) — Commission File Number
• DRMA (company) — Ticker Symbol

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share DRMA The Nasdaq Capital M
• $0.001 — f Common Stock, at an exercise price of $0.001 per share, (iii) series C warrants (the
• $2.04 — per Share and accompanying Warrants was $2.04 and the purchase price per Pre-Funded W
• $2.039 — ed Warrant and accompanying Warrant was $2.039. The Warrants have an exercise price of
• $1.5 million — gregate purchase price of approximately $1.5 million. The purchase price per Share and accom
• $3.7 m — he Private Placement were approximately $3.7 million, after deducting placement agent
• $25,000 — a non-accountable expense allowance of $25,000, and (v) an out-of-pocket expense allow
• $40,000 — ) an out-of-pocket expense allowance of $40,000. In addition, the Company issued to Wai
• $2.55 — mon Stock at an exercise price equal to $2.55 per share. The Placement Agent Warrants
• $12.70 — ary 23, 2025, with an exercise price of $12.70 per share (which exercise price reflect

Filing Documents

• form8-k.htm (8-K) — 55KB
• ex4-1.htm (EX-4.1) — 116KB
• ex4-2.htm (EX-4.2) — 116KB
• ex4-3.htm (EX-4.3) — 119KB
• ex10-1.htm (EX-10.1) — 286KB
• ex10-2.htm (EX-10.2) — 13KB
• ex10-3.htm (EX-10.3) — 186KB
• ex99-1.htm (EX-99.1) — 16KB
• 0001493152-25-029364.txt ( ) — 1299KB
• drma-20251223.xsd (EX-101.SCH) — 4KB
• drma-20251223_def.xml (EX-101.DEF) — 26KB
• drma-20251223_lab.xml (EX-101.LAB) — 36KB
• drma-20251223_pre.xml (EX-101.PRE) — 25KB
• form8-k_htm.xml (XML) — 5KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dermata Therapeutics, Inc. Date: December 29, 2025 By: /s/ Gerald T. Proehl Name: Gerald T. Proehl Title: Chief Executive Officer 4

View Full Filing

View this 8-K filing on SEC EDGAR